Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5937-5944

  Mao, Lijun ^a   Yang, Chunhua ^a   Li, Liantao ^a   Nai, Lanzhou ^a   Fan, Li ^a   Wang, Junqi ^a   Li, Wang ^a   Wen, Rumin ^a   Chen, Jiacun ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Apoptosis; Bladder cancer; Gemcitabine; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; GEMCITABINE; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER SIZE; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; GENETIC THERAPY; HUMANS; MALE; MICE; MICE, INBRED BALB C; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904723632     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1787-2     Document Type: Article

References (21)

1. Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. Br J Urol Int. 2005;96:970-6. (Pubitemid 41531397)
2. Zachos I, Tzortzis V, Mitrakas L, Samarinas M, Karatzas A, Gravas S, et al. Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. Tumour Biol. 2013. doi:10.1007/s13277-013-1547-8.
3. Simons M, Nauseef W, Griffith T. Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer. Immunol Res. 2007;39:79-93. (Pubitemid 47574899)
4. Lamm DL, van der Meijden PM, Morales A. Incidence and treatment of complication of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol. 1992;147:596-600.
5. Brincks EL, Risk MC, Griffith TS. PMN and anti-tumor immunity - the case of bladder cancer immunotherapy. Semin Cancer Biol. 2013;23:183-9.
6. Elnaggar M, Giovannetti E, Peters GJ. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Des. 2012;18:2811-29.
7. Kim TS, Oh JH, Rhew HY. The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer Educ. 2013;4:686-90.
8. Moibi JA, Mak AL, Sun B, Moore RB. Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL. Int J Oncol. 2011;39:61-71.
9. Choi JW, Lee JS, Kim SW, Yun CO. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev. 2012;64:720-9.
10. Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther. 2013;14:1016-23.
11. Tibbetts MD, Zheng L, Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol. 2003;4:404-9. (Pubitemid 36592429)
12. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Human Gene Ther. 2005;16:845-58. (Pubitemid 40982333)
13. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-gemcitabine in bladder cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005;47:69-80. (Pubitemid 39643243)
14. Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: long-term cumulative results of 2 prospective single-institution studies. Cancer. 2011;117:1190-6.
15. Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res. 2013;32:12.
16. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One. 2012;7:e38477.
17. Xie ZH, Quan MF, Liu F, Cao JG, Zhang JS. 5-Allyl-7- gendifluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. BMC Cancer. 2011;11:322.
18. Zhao Y, Li Y, Wang L, Yang H, Wang Q, et al. microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. J Exp Clin Cancer Res. 2013;32:10.
19. Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, et al. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther. 2013;14:146-54.
20. Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int. 2009;104:1286-91.
21. Griffith TS, Stokes B, Kucaba TA, Earel Jr JK, VanOosten RL, Brincks EL, et al. TRAIL gene therapy: frompreclinical development to clinical application. Curr Gene Ther. 2009;9:9-19.